[Table_Rank] 投资评级：买入（维持） 贵州茅台（ [Table_StockNameRptType] 600519） 公司点评 顺利收官，目标理性 ——贵州茅台 2024 年报点评 | 报告日期： | 2025-04-03 | | --- | --- | | [Table_BaseData] 收盘价（元） | 1,549.02 | | 近 12 个月最高/最低 | 1,880.59/1,226.65 | | （元） | | | 总股本（百万股） | 1,256 | | 流通股本（百万股） | 1,256 | | 流通股比例（%） | 100.00 | | 总市值（亿元） | 19,459 | | 流通市值（亿元） | 19,459 | [公司价格与沪深 Table_Chart] 300 走势比较 -35% -19% -3% 13% 29% 4/24 7/24 10/24 1/25 贵州茅台 沪深300 [Table_Author] 分析师：邓欣 执业证书号：S0010524010001 邮箱：dengxin@hazq.com 联系人：郑少轩 执业证书号：S0010124040001 主要观点： ⚫ ...

爱玛科技（ [Table_StockNameRptType] 603529） 公司点评 量价利稳步向上 ——爱玛科技 24A&25Q1 预告点评 | 投资评级：买入（维持） [Table_Rank] | | | --- | --- | | 报告日期： | 2025-04-03 | | [Table_BaseData] 收盘价（元） | 46.97 | | 近 12 个月最高/最低（元） | 47.44/24.72 | | 总股本（百万股） | 862 | | 流通股本（百万股） | 843 | | 流通股比例（%） | 97.80 | | 总市值（亿元） | 405 | | 流通市值（亿元） | 396 | [公司价格与沪深 Table_Chart] 300 走势比较 -30% -7% 16% 39% 62% 4/24 7/24 10/24 1/25 爱玛科技 沪深300 [Table_Author] 分析师：邓欣 执业证书号：S0010524010001 邮箱：dengxin@hazq.com 分析师：成浅之 执业证书号：S0010524100003 邮箱：chengqianzhi@hazq.com 主要观 ...

爱玛科技（ [Table_StockNameRptType] 603529） 邮箱：chengqianzhi@hazq.com 公司点评 量价利稳步向上 ——爱玛科技 24A&25Q1 预告点评 | 投资评级：买入（维持） [Table_Rank] | | | --- | --- | | 报告日期： | 2025-04-03 | | [Table_BaseData] 收盘价（元） | 46.97 | | 近 12 个月最高/最低（元） | 47.44/24.72 | | 总股本（百万股） | 862 | | 流通股本（百万股） | 843 | | 流通股比例（%） | 97.80 | | 总市值（亿元） | 405 | | 流通市值（亿元） | 396 | [公司价格与沪深 Table_Chart] 300 走势比较 -30% -7% 16% 39% 62% 4/24 7/24 10/24 1/25 爱玛科技 沪深300 [Table_Author] 分析师：邓欣 执业证书号：S0010524010001 邮箱：dengxin@hazq.com 分析师：成浅之 执业证书号：S0010524100003 主要观 ...

心脉[Table_StockNameRptType] 医疗（688016） 公司点评 国内政策扰动明显，看好产品出海加速 [Table_Rank] 投资评级：买入（维持） | | | 2025 年 3 月 28 日，公司发布 2024 年年度报告。报告期内，公司实现营 业收入 12.06 亿元（同比+1.61%），归母净利润 5.02 亿元（同比+1.96%）， 扣非净利润 3.95 亿元（同比-14.43%）；单四季度，公司实现营业收入 2.37 亿元（同比-20.75%），归母净利润-0.51 亿元（同比-149.26%），扣 非净利润-1.06 亿元（同比-209.78%）。 ⚫ 点评： ⚫ 核心产品调价+集采轮流覆盖，国内市场承压 报告期内，公司 1Q/2Q/3Q/4Q 单季度分别实现营业收入 3.58/4.29/1.82/2.37 亿元，同比变动 25.4%/27.7%/-31.7%/-20.8%，2H24 承压明显，主要系核心产品价格调整、补缴税款及滞纳金所致。2024 年 9 月，公司主动脉覆膜支架系列产品在医保局的指导下进行了价格调 整，胸主动脉覆膜支架终端价下调约 40%及以上，腹主动脉覆膜 ...

心脉[Table_StockNameRptType] 医疗（688016） 公司点评 国内政策扰动明显，看好产品出海加速 [Table_Rank] 投资评级：买入（维持） | | | 2025 年 3 月 28 日，公司发布 2024 年年度报告。报告期内，公司实现营 业收入 12.06 亿元（同比+1.61%），归母净利润 5.02 亿元（同比+1.96%）， 扣非净利润 3.95 亿元（同比-14.43%）；单四季度，公司实现营业收入 2.37 亿元（同比-20.75%），归母净利润-0.51 亿元（同比-149.26%），扣 非净利润-1.06 亿元（同比-209.78%）。 ⚫ 点评： ⚫ 核心产品调价+集采轮流覆盖，国内市场承压 报告期内，公司 1Q/2Q/3Q/4Q 单季度分别实现营业收入 3.58/4.29/1.82/2.37 亿元，同比变动 25.4%/27.7%/-31.7%/-20.8%，2H24 承压明显，主要系核心产品价格调整、补缴税款及滞纳金所致。2024 年 9 月，公司主动脉覆膜支架系列产品在医保局的指导下进行了价格调 整，胸主动脉覆膜支架终端价下调约 40%及以上，腹主动脉覆膜 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to experience significant operational growth in 2024, driven by new business developments and a strong performance in Q4 2024, with revenue reaching a record high [7][8] - The company has successfully expanded into new projects, including the seating frame and railway container sectors, contributing to a robust revenue increase of 50% year-on-year in 2024 [7] - 2025 is anticipated to be a pivotal year for the company, with key advancements in its core business and the potential for substantial breakthroughs in the automotive seating market [7] Financial Performance Summary - For 2024, the company achieved operating revenue of 2,276 million yuan, a year-on-year increase of 49.9%, and a net profit attributable to the parent company of 137 million yuan, also up by 50.3% [6][7] - The projected financials for 2025-2027 indicate continued growth, with net profits expected to reach 220 million yuan in 2025, 328 million yuan in 2026, and 436 million yuan in 2027, reflecting growth rates of 60.7%, 48.8%, and 32.9% respectively [6][7] - The company's gross margin for 2024 was reported at 17.3%, with expectations for gradual improvement in subsequent years [6][7] Business Development Insights - The company has made significant progress in its R&D capabilities, particularly in the automotive seating sector, with a fully equipped laboratory and a team of experienced professionals [7] - Ongoing collaborations with several well-known automotive manufacturers are expected to enhance the company's market position and product offerings [7] - The successful launch of new products, such as railway containers, demonstrates the company's ability to diversify and innovate within its operational framework [7]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady business progress, with a recent acquisition of a hospital expanding its medical service footprint [5][15] - The company's 2024 annual performance met expectations, with revenue of 1.559 billion RMB, a year-on-year increase of 6.01%, and a net profit of 115 million RMB, up 14.92% [12] - The acquisition of a 51% stake in Changsha Kexin Tumor Hospital for 357 million RMB is expected to enhance the company's medical service capabilities [5][15] - The company is focusing on a dual-driven strategy in medical services and medical devices, anticipating continued growth in both sectors [20] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 1.559 billion RMB, with a net profit of 115 million RMB, and a significant increase in operating cash flow by 36.44% to 259 million RMB [12] - The medical services segment generated 1.192 billion RMB in revenue, a 3.76% increase, while the medical devices segment saw a 14.05% increase to 367 million RMB [12][6] - The company expects revenues of 1.821 billion RMB, 2.114 billion RMB, and 2.308 billion RMB for 2025, 2026, and 2027 respectively, with corresponding net profits of 136 million RMB, 161 million RMB, and 188 million RMB [20][9] Acquisition and Expansion - The acquisition of Changsha Kexin Tumor Hospital is projected to add significant value, with performance commitments ensuring net profits of 57 million RMB, 58 million RMB, and 60 million RMB for 2025 to 2027 [5][15] - The hospital is a comprehensive tumor specialty facility, which will enhance the company's service offerings and operational synergies [15] Strategic Outlook - The company is embracing AI in its operations, developing a three-tier AI+medical framework to enhance service delivery and operational efficiency [16] - The strategic focus on both organic growth and acquisitions in the medical services and devices sectors is expected to drive sustainable growth [20]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to experience significant operational growth in 2024, driven by new business developments and a strong performance in Q4 2024, with a record high quarterly revenue [7][8] - The company has successfully expanded into new projects, including the chair frame and railway container sectors, which are anticipated to contribute significantly to revenue [7] - 2025 is identified as a critical year for fundamental changes in the company, with expectations for breakthroughs in the automotive seating business [7] Financial Performance Summary - For 2024, the company achieved a revenue of 2,276 million yuan, representing a year-on-year increase of 49.9%, and a net profit attributable to the parent company of 137 million yuan, also up by 50.3% [6][7] - The projected revenues for 2025, 2026, and 2027 are 2,812 million yuan, 3,621 million yuan, and 4,511 million yuan, respectively, with growth rates of 23.5%, 28.8%, and 24.6% [6][7] - The net profit attributable to the parent company is expected to reach 220 million yuan in 2025, 328 million yuan in 2026, and 436 million yuan in 2027, with growth rates of 60.7%, 48.8%, and 32.9% respectively [6][7] Key Financial Metrics - The gross margin for 2024 is reported at 17.3%, with expectations to improve to 18.5% in 2025 [6][7] - Return on equity (ROE) is projected to increase from 8.3% in 2024 to 16.2% by 2027 [6][7] - The price-to-earnings (P/E) ratio is expected to decrease from 32.13 in 2024 to 13.36 in 2027, indicating a potential increase in valuation attractiveness over time [6][7]

[Table_StockNameRptType] 一拖股份（601038） 公司点评 盈利端短期承压，坚定看好出海+行业大型高端化 | 投资评级：买入（维持） [Table_Rank] | | | --- | --- | | 报告日期： | 2025-04-02 | | 570 收盘价（元） | 13.75 | | 近 12 个月最高/最低（元） | 20.49/13.03 | | 总股本（百万股） | 1123.65 | | 流通股本（百万股） | 731.71 | | 流通股比例（%） | 65.12 | | 总市值（亿元） | 154.50 | | 流通市值（亿元） | 100.61 | [公司价格与沪深 Table_Chart] 300 走势比较 -30% -20% -10% 0% 10% 20% 30% 一拖股份 沪深300 [分析师：张帆 Table_Author] 执业证书号：S0010522070003 邮箱：zhangfan@hazq.com 相关报告 ⚫ 投资建议 1.《国内农机领军者，立足中国，放眼 世界》2024-09-26 2.《业绩短期承压，看好未来长期发展》 2024-11-08 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 11.90 billion yuan for 2024, a year-on-year increase of 3.21%, while the net profit attributable to shareholders was 0.92 billion yuan, a decrease of 7.52% [4] - The company is focusing on enhancing its overseas market presence and high-end product offerings, despite short-term pressure on profitability [6][7] Financial Performance Summary - For 2024, the company achieved a revenue of 11.90 billion yuan, with a year-on-year growth of 3.21% [4] - The net profit attributable to shareholders was 0.92 billion yuan, reflecting a decline of 7.52% year-on-year [4] - The gross margin and net margin for 2024 were 14.78% and 7.82%, respectively, both showing a decrease [5] - The company sold 74,300 large and medium-sized tractors in 2024, marking a 2.73% increase year-on-year [6] - The company expects revenues of 12.56 billion yuan, 13.84 billion yuan, and 15.25 billion yuan for 2025, 2026, and 2027, respectively [7] - The projected net profit attributable to shareholders for 2025, 2026, and 2027 is 0.99 billion yuan, 1.09 billion yuan, and 1.20 billion yuan, respectively [7] Cost Management and Profitability - The company has optimized its cost management, with sales, management, and R&D expense ratios at 1.31%, 2.98%, and 4.34%, respectively [5] - The increase in R&D expense ratio is attributed to investments in high-end, intelligent, and green technology projects [5] Market Position and Strategy - The company is enhancing its product lineup and market competitiveness, particularly in the tractor segment [6] - The company is expanding its overseas market strategy, including a contract for supplying 301 tractors to Nigeria [6]